[ad_1]
Australians spend more than $ 12 billion a year on the care of our pets, with veterinary fees being the most important. Unfortunately, medications for our downy friends can also have terrible side effects, such as nausea, loss of appetite, depression, and internal bleeding.
It's here that CannPal, an animal-based pharmaceutical company, hopes to make a difference. In collaboration with CSIRO as part of its Kick-start program, the company is exploring ways to avoid these negative effects with medicinal cannabis.
The CannPal website discusses the science behind research, indicating that all mammals have biological and neurological systems. "The endocannabinoid system (ECS) is involved in a variety of physiological processes, including appetite, sensation of pain, nausea, mood and memory, without some of the side effects that are commonly badociated current treatments for nutritional cannabinoids. "Cannabinoids such as cannabidiol (CBD) and tetrahydrocannabinol (THC) are naturally occurring compounds in trace amounts in many plants, including (but not limited to not exclusively) in Cannabis.Cannabinoids have been grown for thousands of years, partly because they interact only with ECS. "
CSIRO reports that this makes it so Cannabis is a good choice for eliminating arthritis, cancer, joint skin and digestive problems in pets.
This makes it an excellent choice to combat the symptoms in pets resulting from diseases such as arthritis and cancer; as well as other articular, cutaneous and digestive disorders.
Of course, not all organs and digestive agents are identical – the drug must therefore be specifically developed and optimized for different animals.
CSIRO is investigating new production processes to help this optimization – including its patented MicroMax technology, which creates a powder containing high levels of cannabis oils.
"MicroMax is a microencapsulation technology, which means that the powder can be optimized" In this case, we are looking to see if MicroMax is an effective way of mixing cannabis oils with other beneficial oils. A way that maximizes the amount of medicinal cannabis that can be included, and protects its potency from its manufacture until its final absorption into the stomach of a pet. o Determine where in the stomach the powder dissolves, to ensure maximum effect. "
So far, no calendar has been placed on when the research will be completed, let alone when we can see these products in the mainstream market." However, the process of selecting dogs for An NSW trial was completed in March 2018 with a dosing in early April. The site indicates that the blood sample badysis should be completed in May.
L & # 39; The study would have been conducted in two phases, including eleven dogs for phase one and forty-eight for phase two.
CannPal also obtained export permits from Health Canada and signed a manufacturing contract with Jaychem Industries Ltd, New Zealand.
We are anxious to hear about the test results and hope that the drugs will help beloved people.
You can watch a video explaining the endocannabinoid signaling system here :
Source link
